Project Grant DP2CA301099
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$1.4M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Cancer Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel CAR-T immunotherapeutic for the treatment of pancreatic cancer. The key products to be delivered include: Engineering CAR-T cells that target the MUC16 antigen and secrete a VIP receptor antagonist (ANT308-FC) to disrupt the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). This aims to enhance the...
This $1,130,538 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC) using a newly developed anti-Tn (AREMAB6) monoclonal antibody. The key objectives are to: 1) determine how the Tn antigen enhances PDAC progression and identify Tn-expressing glycoproteins; 2) validate the role of natural killer cells in AREMAB6-mediated...
This Project Grant award of $414,482 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an improved oncolytic virus therapy for treating glioblastoma, an aggressive type of brain cancer. The key goals are to enhance the therapeutic efficacy of the Semliki Forest Virus (SFV) through directed evolution and engineering the virus to express a cancer-targeting peptide. The research aims to create a...
This Project Grant award of $416,040 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel oncolytic herpes simplex virus-1 (OHSV-1) variant called OHSV-1(ICP6MUT) that can overcome the limitations of the FDA-approved oncolytic virus T-VEC. The key objectives are to: (1) determine how OHSV-1(ICP6MUT)-triggered necroptosis (a highly immunogenic form of cell death) reshapes the melanoma tumor microenvironment compared to T-VEC in mouse models, and (2)...
This $420,335 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding the role of lytic viral gene expression in the development and maintenance of oncogenic gammaherpesvirus-associated cancers. The University of Arkansas for Medical Sciences (UAMS) is leading this 2-year research project to test the hypothesis that lytic gene expression is...
This Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) aims to advance a local controlled release platform for intratumoral delivery of hyaluronidase to improve the efficacy of systemically administered drugs for pancreatic ductal adenocarcinomas (PDAC). The award totals $599,474 and will fund a 5-year project from Sep 1, 2024 to Aug 31, 2029. The key products and services to be delivered through this grant include: 1) using...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $408,966 to support research investigating the use of pharmacological small molecules to enhance the effectiveness of vesicular stomatitis virus (VSV)-based oncolytic viral therapy for treating advanced melanoma. The project aims to determine if locally inhibiting the PI3K/AKT/mTOR signaling pathway in tumors can create conditions for improved intratumoral spread and cancer cell...
This $602,550 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) supports adoptive cellular therapy research for pancreatic cancer. The awardee, the University of Nebraska Medical Center (UNMC), will conduct innovative biomedical research to develop novel therapeutic approaches, perform clinical trials, and provide technical expertise in this critical medical field. As a prominent academic research...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $654,197 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on pancreatic cancer patient-derived xenograft (PDX) tumor models. The research aims to: Define the molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how...